Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy

被引：0
|
作者：
Sestak, Ivana
Regan, Meredith
Dodson, Andrew
Viale, Giuseppe
Thurlimann, Beat
Colleoni, Marco
Cuzick, Jack
Dowsett, Mitch
机构：
[1] QMUL, Wolfson Inst Prevent Med, Ctr Canc Prevent, London, England
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Ralph Lauren Ctr Breast Canc Res, London, England
[4] European Inst Oncol, Milan, Italy
[5] Kantonsspital St Gallen, St Gallen, Switzerland
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS6-01
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
    Dowsett, Mitch
    Sestak, Ivana
    Regan, Meredith M.
    Dodson, Andrew
    Viale, Giuseppe
    Thuelimann, Beat
    Colleoni, Marco
    Cuzick, Jack
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (19) : 1941 - +
  • [2] Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5 (vol 14, pg 234, 2019)
    Dowsett, Mitch
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) : 656 - 656
  • [3] Improved use of clinical variables for prognosis of distant recurrence in patients with ER plus breast cancer treated with 5 years endocrine therapy.
    Sestak, Ivana
    Yeo, Belinda
    Dodson, Andrew
    Dowsett, Mitch
    Cuzick, Jack M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients
    Richman, Juliet
    Schuster, Gene
    Buus, Richard
    Lopez-Knowles, Elena
    Dowsett, Mitch
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (01) : 195 - 205
  • [5] Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer
    Richman, Juliet
    Dowsett, Mitch
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (05) : 296 - 311
  • [6] Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer
    Juliet Richman
    Mitch Dowsett
    Nature Reviews Clinical Oncology, 2019, 16 : 296 - 311
  • [7] The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer
    Tajiri, Wakako
    Ijichi, Hideki
    Takizawa, Katsumi
    Koi, Yumiko
    Masuda, Takanobu
    Ueo, Hiroki
    Koga, Chinami
    Nakamura, Yoshiaki
    Taguchi, Kenichi
    Okamoto, Masahiro
    Tokunaga, Eriko
    BREAST CANCER, 2021, 28 (01) : 67 - 74
  • [8] The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer
    Wakako Tajiri
    Hideki Ijichi
    Katsumi Takizawa
    Yumiko Koi
    Takanobu Masuda
    Hiroki Ueo
    Chinami Koga
    Yoshiaki Nakamura
    Kenichi Taguchi
    Masahiro Okamoto
    Eriko Tokunaga
    Breast Cancer, 2021, 28 (1) : 67 - 74
  • [9] Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy
    Masahiro Ito
    Masakazu Amari
    Akiko Sato
    Masahiro Hikichi
    Natsuko Tsurumi
    Hinano Otofuji
    Shigehira Saji
    Breast Cancer Research and Treatment, 2025, 209 (3) : 503 - 512
  • [10] Usefulness of CTS5 for the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer
    Tajiri, W.
    Masuda, T.
    Ijichi, H.
    Koga, C.
    Tanaka, J.
    Nakamura, Y.
    Okamoto, M.
    Tokunaga, E.
    BREAST, 2019, 44 : S18 - S18
12345